Future directions for serotonin and antidepressants

ACS Chemical Neuroscience

Volumn 4, Issue 1, 2013, Pages 5-8

  Artigas, Francesc ^a  

^a INST D INVESTIGACIONS B   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; PAROXETINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; VILAZODONE; VORTIOXETINE;

DRUG MECHANISM; DRUG STRUCTURE; PRIORITY JOURNAL; REVIEW;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG DISCOVERY; EXCITATORY AMINO ACID AGENTS; FORECASTING; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 84872567287     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn3001125     Document Type: Review

References (21)

1. Smith, K. (2011) Trillion-dollar brain drain Nature 478, 15
2. Danish University Antidepressant Group (1986) Citalopram: Clinical effect profile in comparison with clomipramine. a controlled multicenter study Psychopharmacology (Berlin, Ger.) 90, 131-138
3. Danish University Antidepressant Group (1990) Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study J. Affective Disord. 18, 289-299
4. Tollefson, G. D. and Holman, S. L. (1994) How long to onset of antidepressant action: A meta-analysis of patients treated with fluoxetine or placebo Int. Clin. Psychopharmacol. 9, 245-250 (Pubitemid 24374885)
5. Thase, M. E., Entsuah, A. R., and Rudolph, R. L. (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors Br. J. Psychiatry 178, 234-241 (Pubitemid 32183606)
6. Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., Luther, J. F., Shores-Wilson, K., and Rush, A. J. (2006) Medication augmentation after the failure of SSRIs for depression N. Engl. J. Med. 354, 1243-52
7. Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., Mosolov, S. N., Neznanov, N. G., Reznik, A. M., Smulevich, A. B., Tochilov, V. A., Johnson, B. G., Monn, J. A., and Schoepp, D. D. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase II clinical trial Nat. Med. 13, 1102-1107 (Pubitemid 47517511)
8. Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., and Manji, H. K (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63, 856-864 (Pubitemid 44188478)
9. 1A antaognists Trends Neurosci. 19, 378-383 (Pubitemid 26270513)
10. Artigas, F., Celada, P., Laruelle, M., and Adell, A. (2001) How does pindolol improve antidepressant action? Trends Pharmacol. Sci. 22, 224-228 (Pubitemid 32411522)
11. 1A receptors J. Neurosci. 18, 10150-10156 (Pubitemid 28543788)
12. Scorza, M. C., Llado-Pelfort, L., Oller, S., Cortes, R., Puigdemont, D., Portella, M. J., Perez-Egea, R., Alvarez, E., Celada, P., Perez, V., and Artigas, F (2012). Preclinical and clinical characterization of the selective serotonin-1A receptor antagonist DU-125530 for antidepressant treatment. Br. J. Pharmacol. Epub. PMID: 22050051
13. 1A autoreceptors Mol. Psychiatry 17, 612-623
14. 1A receptor agonists Eur. Neuropsychopharmacol. 20, 641-654
15. Lladó-Pelfort, L., Assié, M. B., Newman-Tancredi, A., Artigas, F., and Celada, P. (2010) Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors Br. J. Pharmacol. 160, 1929-1940
16. Diaz, S. L., Doly, S., Narboux-Neme, N., Fernandez, S., Mazot, P., Banas, S. M., Boutourlinsky, K., Moutkine, I., Belmer, A., Roumier, A., and Maroteaux, L. (2012) 5-HT(2B) receptors are required for serotonin-selective antidepressant actions Mol. Psychiatry 17, 154-163
17. Lucas, G., Rymar, V. V., Du, J., Mnie-Filali, O., Bisgaard, C., Manta, S., Lambas-Senas, L., Wiborg, O., Haddjeri, N., Pineyro, G., Sadikot, A. F., and Debonnel, G. (2007) Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action Neuron 55, 712-725 (Pubitemid 47334877)
18. Wesolowska, A. and Nikiforuk, A. (2007) Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression Neuropharmacology 52, 1274-1283 (Pubitemid 46527703)
19. 7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents J. Pharmacol. Exp. Ther. 321, 690-698 (Pubitemid 46624521)
20. Page, M. E., Cryan, J. F., Sullivan, A., Dalvi, A., Saucy, B., Manning, D. R., and Lucki, I. (2002) Behavioral and neurochemical effects of 5-(4-[4-(5-cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2- carboxamide (EMD 68843): A combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist J. Pharmacol. Exp. Ther. 302, 1220-1227 (Pubitemid 34920246)
21. Mork, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sanchez, C., Fischer, C. W., Liebenberg, N., Wegener, G., Bundgaard, C., Hogg, S., Bang-Andersen, B., and Stensbol, T. B. (2012) Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder J. Pharmacol. Exp. Ther. 340, 666-675